Lupin's Oxcarbazepine ER tablets are bioequivalent to Oxtellar XR, and treat partial-onset seizures in patients 6+. Manufactured in India. They match the $206 million annual U.S. sales of the reference drug.

• Available in 150 mg, 300 mg, and 600 mg as a generic alternative to Oxtellar XR.
• Produced at Lupin's Nagpur facility, ensuring quality and regulatory compliance.
• Lupin, a global pharmaceutical leader, offers products in over 100 markets with diverse therapeutic options.